| 創建日期 | 上櫃日期 | 董事長 | 總經理 |
|---|---|---|---|
| 90/02/06 | 101/01/10 | 林齊國 | 林明毅 |
| EPS | 本益比 | 股價淨值比 | 現金殖利率 |
| 2.65(Q2) | 19.86 | 9.9 | 4.87% |
| 實收資本額 | 已發行普通股 | ||
| 544,630,000 | 54,463,000 | ||
| 主要經營業務 | |||
| 西藥製造業、醫療器材設備製造業、化粧品製造業國際貿易業(兼營與前述業務相關之進出口貿易業務)研究、開發、製造及銷售生醫材料級膠原蛋白及相關產品 | |||
| 公司網址 | |||
| sunmaxbiotech.com | |||
雙美(4728) 月營收報表
| 年度/月份 | 營業收入（單位：千元） | 累計營業收入（單位：千元） | |||||
|---|---|---|---|---|---|---|---|
| 單月營收 | 去年同月營收 | 單月月增率 | 單月年增率 | 累計營收 | 去年累計營收 | 累積年增率 | |
| 2023/08 | 164,583 | 116,476 | 9.7% | 41.3% | 1,139,673 | 865,135 | 31.7% |
| 2023/07 | 149,972 | 105,317 | -14% | 42.4% | 975,090 | 748,659 | 30.2% |
| 2023/06 | 174,416 | 106,806 | 48.7% | 63.3% | 825,118 | 643,342 | 28.3% |
| 2023/05 | 117,265 | 111,056 | -16.1% | 5.6% | 650,702 | 536,536 | 21.3% |
| 2023/04 | 139,718 | 102,505 | -27.6% | 36.3% | 533,437 | 425,480 | 25.4% |
| 2023/03 | 192,944 | 102,816 | 28.7% | 87.7% | 393,719 | 322,975 | 21.9% |
| 2023/02 | 149,937 | 112,068 | 194.9% | 33.8% | 200,775 | 220,159 | -8.8% |
| 2023/01 | 50,838 | 108,091 | -53.4% | -53% | 50,838 | 108,091 | -53% |
| 2022/12 | 109,127 | 129,879 | -14.4% | -16% | 1,394,253 | 1,033,939 | 34.8% |
| 2022/11 | 127,430 | 18,530 | -15.6% | 587.7% | 1,285,126 | 904,060 | 42.2% |
| 2022/10 | 151,069 | 135,443 | 6.8% | 11.5% | 1,157,696 | 885,530 | 30.7% |
| 2022/09 | 141,492 | 92,266 | 21.5% | 53.3% | 1,006,627 | 750,087 | 34.2% |
| 2022/08 | 116,476 | 86,623 | 10.6% | 34.5% | 865,135 | 657,821 | 31.5% |
| 2022/07 | 105,317 | 72,555 | -1.4% | 45.2% | 748,659 | 571,198 | 31.1% |
| 2022/06 | 106,806 | 75,631 | -3.8% | 41.2% | 643,342 | 498,643 | 29% |
| 2022/05 | 111,056 | 63,270 | 8.3% | 75.5% | 536,536 | 423,012 | 26.8% |
| 2022/04 | 102,505 | 92,229 | -0.3% | 11.1% | 425,480 | 359,742 | 18.3% |
| 2022/03 | 102,816 | 100,264 | -8.3% | 2.5% | 322,975 | 267,513 | 20.7% |
| 2022/02 | 112,068 | 76,111 | 3.7% | 47.2% | 220,159 | 167,249 | 31.6% |
| 2022/01 | 108,091 | 91,138 | -16.8% | 18.6% | 108,091 | 91,138 | 18.6% |
| 2021/12 | 129,879 | 79,956 | 600.9% | 62.4% | 1,033,939 | 855,851 | 20.8% |
| 2021/11 | 18,530 | 83,463 | -86.3% | -77.8% | 904,060 | 775,895 | 16.5% |
| 2021/10 | 135,443 | 94,330 | 46.8% | 43.6% | 885,530 | 692,432 | 27.9% |
| 2021/09 | 92,266 | 119,219 | 6.5% | -22.6% | 750,087 | 598,102 | 25.4% |
| 2021/08 | 86,623 | 87,280 | 19.4% | -0.8% | 657,821 | 478,883 | 37.4% |
| 2021/07 | 72,555 | 55,549 | -4.1% | 30.6% | 571,198 | 391,603 | 45.9% |
| 2021/06 | 75,631 | 67,572 | 21.7% | 11.9% | 498,643 | 336,054 | 48.4% |
| 2021/05 | 62,160 | 81,980 | -16.6% | -24.2% | 423,012 | 307,098 | 37.7% |
| 2021/04 | 74,545 | 54,113 | -37.4% | 37.8% | 360,852 | 225,118 | 60.3% |
| 2021/03 | 119,058 | 59,356 | 56.4% | 100.6% | 286,307 | 171,005 | 67.4% |
| 2021/02 | 76,111 | 36,164 | -16.5% | 110.5% | 167,249 | 111,649 | 49.8% |
| 2021/01 | 91,138 | 75,485 | -39.5% | 20.7% | 91,138 | 75,485 | 20.7% |
| 2020/12 | 150,787 | 76,147 | 12.3% | 98% | 913,762 | 593,960 | 53.8% |
| 2020/11 | 134,268 | 53,884 | 114.5% | 149.2% | 762,975 | 517,813 | 47.3% |
| 2020/10 | 62,594 | 23,715 | -25.1% | 163.9% | 628,707 | 463,929 | 35.5% |
| 2020/09 | 83,565 | 79,363 | 46.7% | 5.3% | 566,113 | 440,214 | 28.6% |
敦陽科(2480) 歷年營收季增率
| 年度/季別 | 營收季增率 | 近4季營收季增率 | 年度/季別 | 營收季增率 | 近4季營收季增率 |
|---|---|---|---|---|---|
| 2023Q2 | 10.38% | 3.67% | 2020Q3 | 0.64% | -0.16% |
| 2023Q1 | -7.65% | 2.11% | 2020Q2 | 1.42% | 2.30% |
| 2022Q4 | 12.35% | -1.90% | 2020Q1 | -17.40% | -1.54% |
| 2022Q3 | 0.72% | 0.38% | 2019Q4 | 17.81% | 5.29% |
| 2022Q2 | 4.32% | 1.84% | 2019Q3 | 11.85% | 6.59% |
| 2022Q1 | -20.83% | 1.97% | 2019Q2 | -13.72% | 3.85% |
| 2021Q4 | 22.14% | 6.73% | 2019Q1 | 6.63% | 1.91% |
| 2021Q3 | 7.21% | 4.99% | 2018Q4 | 28.08% | 5.76% |
| 2021Q2 | 5.14% | 3.39% | 2018Q3 | 0.07% | -2.15% |
| 2021Q1 | -8.23% | 2.46% | 2018Q2 | -21.85% | 1.51% |
| 2020Q4 | 17.92% | -0.17% | 2018Q1 | 23.83% | 5.33% |
評論0